Lymphoma News Archives > Page 2 of 3 > Lymphoma Research Foundation

ECHELON-2 Trial Demonstrates “Practice-Changing” Results for Peripheral T-Cell Lymphomas

FDA Approves Ibrutinib (IMBRUVICA) in Combination with Obinutuzumab (GAZYVA) for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

U.S. Food and Drug Administration Approves Brentuximab Vedotin (ADCETRIS) for Frontline Treatment of Peripheral T-Cell Lymphoma (PTCL)

In Memoriam: Paul Allen

U.S. Food and Drug Administration Approves Duvelisib (COPIKTRA) for Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and Follicular Lymphoma

U.S. Food and Drug Administration Approves Ibrutinib (IMBRUVICA) Plus Rituximab (RITUXAN) for Waldenström Macroglobulinemia (WM)

U.S. Food and Drug Administration Approves Mogamulizumab-kpkc (Poteligeo) for Two Most Common Types of Cutaneous T-Cell Lymphoma

U.S. Food and Drug Administration Approves Pembrolizumab (Keytruda) for Relapsed/Refractory Primary Mediastinal B-Cell Lymphoma (PMBCL)

U.S. Food and Drug Administration Approves Venetoclax (VENCLEXTA) For Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia – With or Without 17p Deletion

U.S. Food and Drug Administration Approves Tisagenlecleucel For Relapsed/ Refractory Large B-cell Lymphoma